A clinical program that helps autoimmune employees safely reduce — and eliminate — their biologic medications.
By the time a patient appears on your biologic spend report, they've been accumulating disease burden for years. Fragmented care, failed medications, and a growing risk that will cost your plan far more than the drug line.
Patient is already on a specialty biologic. Thymos assesses taper readiness, supports the clinical exit, and monitors for flare. The expensive drug stops. The savings start.
Patient has failed first-line therapy and is being evaluated for a biologic. Thymos intercepts at the clinical decision point — before the expensive Rx is written. The biologic never starts.
Thymos uses complex claims patterns and patient-reported symptom data to surface likely autoimmune patients before they're ever diagnosed — connecting them to care earlier and stopping the snowball before it has a chance to grow. The entire downstream cost curve never forms.
| Drug class | GPI | Fills/yr your plan |
AWP/fill | Est. spend/yr |
|---|
Biologics are prescribed for life — by default. Physicians manage flares. Nobody manages the exit.
Thymos pairs autoimmune patients with clinicians who actively work toward reducing — and eventually eliminating — their biologic medication. Safely. Measurably.
Every month a patient advances through the program, the cost asymmetry compounds.
Tapering takes months. But every patient who engages pays back their full program cost — and then some.
Based on 3-archetype model: early adopter (month 6), mid-cycle (month 12), slow adopter (month 18–19).
Conservative estimate. $5K/month average biologic AWP.
Assumes 10 program participants, avg biologic AWP $5K/mo, mixed engagement cohort (early/mid/late adopters). Actual PBM data will sharpen these numbers.
Three cost tiers, three adoption timings. Cards above show the blended average across early, mid, and late adopters for each tier. The higher the biologic cost, the more the ROI compounds — even at average engagement.
De-identified symptom burden at enrollment (M0) vs. current (M6). Lower is better — population norm T=50. Engaged patients: mean −12 points.
Mean improvement for engaged patients: −12 points at M6. Non-engagers show no change — but represent only 20% of the cohort and are already modeled into the ROI.
$500/patient/month · 24-month commitment. One patient stopping a high-cost biologic pays for the whole program — and keeps paying, indefinitely.
Thymos drafts the data request. You forward it to your health plan or PBM. They return a count — no PHI, no claims detail.
A personal letter from Thymos Health — voluntary, no-pressure, no clinical jargon. Members can call or go online to learn more.
De-identified. Actual fills. Cost math done for you. Pipeline, KPIs, therapeutic class breakdown — all in one page.
The model above uses industry averages. If you want to get more precise on your company's actual opportunity, one ask to your PBM is all it takes.